AOD-9604 Dosage for Fat Loss: What the Trials Show

Why Does the AOD-9604 Fat Loss Peptide Story Break Down?

The AOD-9604 dosage for fat loss with the best human result was 1 mg a day, in a 12-week randomised trial. That group lost an average of 2.6 kg, against 0.8 kg on placebo. A 10 mg a day group lost less. A 24-week trial of 536 subjects failed to produce significant weight loss.

The 1 mg and 24-week figures appear in two reviews of obesity drugs. The 10 mg result appears in only one of them (PMC3136748). The reviews give the dose in milligrams a day. They do not say how it was given in the trials. AOD-9604 has no approved dose, because it is not an approved medicine.

AOD-9604 is a short piece of human growth hormone (hGH). Cox and colleagues describe it as hGH amino acids 177-191 with one extra amino acid, tyrosine, at the start. In a 2001 mouse and cell study, it cut weight gain in obese mice. In the same study's cell tests, it did not interact with the growth hormone receptor. In obese rats, it did not harm insulin sensitivity, the body's response to insulin.

So the animal case looked strong, and the human trials did not match it. This page reads the dose question through the primary papers. It is for educational purposes only. AOD-9604 is an unapproved investigational compound. A qualified clinician can advise on any use of it.

How Does the AOD-9604 Fat Loss Mechanism Work?

Lipolysis is the breakdown of stored fat into fatty acids and glycerol. In rats given AOD-9604, fat tissue showed more fat-breaking activity. In obese mice, it raised fat burning and plasma glycerol. Plasma glycerol is a blood marker of lipolysis.

The beta-3 receptor is the main fat-releasing receptor on fat cells. In obese mice, AOD-9604 raised beta-3 receptor RNA, the gene message a cell reads to build the receptor. In mice bred without that receptor, long-term AOD-9604 did not change body weight or raise lipolysis.

That might suggest AOD-9604 works through the beta-3 receptor. The study authors concluded otherwise. They found its fat-releasing action is not carried directly through the beta-3 receptor. In a short test, it still raised energy use and fat burning in mice with no beta-3 receptor. Their reading is that the extra receptor may make fat cells release fat more readily.

What Does the AOD-9604 Fat Loss Evidence Actually Show?

Three animal studies carry the weight.

Ng et al., Hormone Research, 2000: Ng and colleagues fed AOD-9604 to obese Zucker rats for 19 days. The dose was 500 mcg/kg a day. Weight gain was cut by more than 50% against control rats. That is 15.8 g against 35.6 g. Fat tissue showed higher lipolytic activity, meaning more fat breakdown. Unlike long-term intact hGH, it did not harm insulin sensitivity.

Heffernan et al., Int J Obesity, 2001: Heffernan and colleagues treated obese ob/ob mice, a strain bred to become obese, for 14 days. They gave hGH, AOD-9604 or saline through small pumps placed in the body. Both hormones cut weight gain. Both raised fat burning and plasma glycerol. Unlike hGH, AOD-9604 did not raise blood sugar or cut insulin release. In cell tests it did not compete for the hGH receptor or make cells multiply.

Heffernan et al., Endocrinology, 2001: the follow-up study treated obese mice for 14 days. The drug went into the belly cavity (intraperitoneal). Both hGH and AOD-9604 cut body weight and body fat. Both raised beta-3 receptor RNA in obese mice to levels like those in lean mice. In knockout mice, bred with no beta-3 receptor, long-term treatment did not change weight.

One detail is easy to miss. In a short test, AOD-9604 still raised energy use and fat burning in the knockout mice. So the authors concluded that its fat-releasing action does not run directly through the beta-3 receptor.

All three studies were in rodents. None of them sets a human dose.

A fourth rodent (mouse) study tested AOD-9401, a related growth hormone fragment, not AOD-9604. Obese mice got it by mouth for 30 days. From day 16, they gained less weight than mice given saline, yet they ate the same amount. In the lab, it also raised fat breakdown in human fat tissue (Heffernan et al. 2000).

What Did the AOD-9604 Clinical Trials Fat Loss Results Show?

The 12-week trial is the most quoted result. Subjects on 1 mg a day lost an average of 2.6 kg. The placebo group lost 0.8 kg. A review of new obesity drugs calls it a randomised trial.

The same review adds two facts. First, the result did not rise with dose. People on 10 mg a day lost less than people on 1 mg a day. Second, a 24-week trial of 536 subjects failed to produce significant weight loss. A 2013 review by Misra in Current Cardiology Reviews gives the same 12-week result. It also reports the same failed 24-week trial. It does not mention the 10 mg group. It records that development stopped in 2007.

Neither review explains why the larger trial failed. Neither gives the dose used in it. Any reason offered for the failure is a guess, not a finding.

A separate safety summary covers six placebo-controlled trials run from 2001 to 2006 (Stier and colleagues, 2013). They enrolled 893 adults, and most were obese. Doses were single doses into a vein (IV) of 25 to 400 mcg per kg, or 0.25 to 54 mg a day by mouth. The longest trial randomised 502 obese adults to 0.25, 0.5 or 1 mg a day, or placebo, for 24 weeks. Of 534 people enrolled, 502 were randomised. The reviews above give 536 subjects for the 24-week trial. IGF-1 is a growth factor the body makes in response to growth hormone. IGF-1 and blood sugar tests did not differ from placebo. The summary reports safety only. It gives no weight-loss results.

All three authors declared financial ties to Metabolic Pharmaceuticals, the company behind the trials. Read the safety finding with that in mind.

Did the Trial Population Change the Result?

No source cited here shows that it did. The idea comes from the mouse work. In obese mice, beta-3 receptor RNA was low. AOD-9604 raised it to the level seen in lean mice.

That finding was in mice, over 14 days. Neither review reports receptor levels in the trial subjects. Neither review describes who was in the trials, either. So the mouse data cannot say how any trial group would respond. None of the sources cited on this page reports an AOD-9604 trial in lean people.

Is the 4.6x Visceral Selectivity Claim Solid?

The 4.6x visceral fat figure is quoted widely online. None of the sources cited on this page reports it. We searched PubMed for AOD9604 in October 2026. No abstract we found reports it. So the figure has no traceable primary source, and this page does not rely on it.

Visceral fat is the fat packed around the organs inside the belly. None of the AOD-9604 studies cited here measured where in the body the fat was lost.

What Is the AOD-9604 Dosage for Fat Loss?

No regulator has set an AOD-9604 dosage for fat loss. The doses below are the ones the cited sources report, in their own terms.

In people, the 12-week trial tested 1 mg a day and 10 mg a day, and the 1 mg a day group did best. In rats, Ng and colleagues gave 500 mcg/kg a day by mouth for 19 days. In rabbits with knee damage, Kwon and Park injected 0.25 mg into the knee joint once a week.

No source here explains why 10 mg a day did worse than 1 mg a day. No source here tests cycles or breaks. Doses quoted online without a named study are not used on this page.

This is a summary of published research, not a medical prescription. A qualified clinician can advise on any protocol in your own context. For checked sources of research-grade compounds, our recommended sources page has the list.

Does AOD-9604 Dosing for Fat Loss Depend on Timing?

None of the sources cited on this page tested timing. None compared fasted with fed dosing, or dosing before exercise. So the record cannot say whether timing changes the result.

Our AOD-9604 dosage and cycling guide covers timing and break length in more depth. Our guide on how to inject peptides correctly covers the technique.

Why Is Lipolysis Not the Same as Fat Loss?

Lipolysis is the release of free fatty acids from stored fat, called triglycerides. Fat loss is a drop in fat tissue mass over time. The two are linked, but they are not the same event. Fatty acids that are released but not burned can be stored again. That repacking is called re-esterification.

The mouse work measured both steps. Heffernan and colleagues saw raised plasma glycerol and raised fat burning. Ng and colleagues saw more fat breakdown in rat fat tissue. The two human trial reports cited here give weight results only. So they cannot show which step fell short in people.

How Safe Is AOD-9604 in the Trial Record?

The published safety record is thin. The FDA lists AOD-9604 on its page of bulk drug substances for compounding that may present significant safety risks. It sits in the group that was nominated and then withdrawn.

The FDA says it has identified no, or only limited, safety information on AOD-9604. It says it has also identified serious adverse events that may be linked to it, though cause is not clear. It flags a possible risk of immune reactions, called immunogenicity, for some routes of use.

The safety summary by Stier and colleagues reports side effect rates like placebo at doses up to 27 mg a day by mouth. At 54 mg a day, people had more headache, diarrhoea and wind.

The two obesity reviews cited here give weight results, not side effects. Cox and colleagues studied how AOD-9604 breaks down in blood serum and urine in the lab. Their paper ran in Drug Testing and Analysis in 2015. One breakdown product, made of the amino acids CRSVEGSCG, was far more stable than the parent peptide. Testing for it may widen the window in which use can be detected.

Does AOD-9604 Do Anything Beyond Fat Loss?

The clearest data outside fat loss comes from rabbit knees. Kwon and Park did this work in 2015. They damaged the knees of 32 rabbits with collagenase, an enzyme. This mimics osteoarthritis, a wear-and-tear joint disease. Then they gave weekly shots into the joint.

Hyaluronic acid (HA) is a gel found in normal joint fluid. Each group got one shot type: saline, HA, AOD-9604, or AOD-9604 with HA. All three treatments gave better cartilage scores than saline. AOD-9604 with HA did best, and those rabbits limped for the shortest time.

This was an animal study. None of the sources cited here reports a human trial of AOD-9604 for joints. Our cartilage and osteoarthritis peptide protocol guide covers other compounds studied for joints. So does our list of the best peptides for injury recovery in 2026.

Tesamorelin vs AOD-9604 for Fat Loss: Which Has the Stronger Data?

Tesamorelin has the stronger regulatory record. It holds an FDA approval for one use, and AOD-9604 holds none. The FDA-approved label for Egrifta WR lists one use. That is to reduce excess belly fat in adults with HIV and lipodystrophy, an abnormal shift in body fat.

The two work by different routes. Tesamorelin is a man-made analogue of growth hormone-releasing factor. That is the brain signal that tells the body to make its own growth hormone. Its label warns that it can cause glucose intolerance, meaning poorer blood sugar control. In cell tests, AOD-9604 did not compete for the growth hormone receptor. No study cited here has compared the two head to head.

Our tesamorelin versus ipamorelin comparison covers how two growth hormone compounds differ.

For weight loss, semaglutide holds FDA approval and AOD-9604 does not. A qualified clinician can advise on any choice between them.

Our growth hormone secretagogues versus hGH comparison covers the IGF-1 and blood sugar trade-offs. IGF-1 is a growth factor the body makes in response to growth hormone. Our CJC-1295 and ipamorelin stack protocol guide covers that pairing.

Which Wins on HGH Fragment 176-191 vs AOD-9604 for Fat Loss?

No study cited here has compared them, so neither can be named the winner. The sources do not even agree on whether they are one compound.

Cox and colleagues define AOD-9604 as hGH amino acids 177-191 with one extra amino acid, tyrosine, at the start. One 2026 review calls AOD9604 hGH 176-191. A 2026 drug-testing paper treats them as two different compounds.

For buyers, the label matters less than what is in the vial. Our guides on how to read a peptide certificate of analysis and how to know if your peptides are real cover testing.

Who Is AOD-9604 Fat Loss Research Actually For?

The published record covers a narrow set of subjects.

• Obese rodents. Obese Zucker rats and ob/ob mice gained less weight on AOD-9604.
• People in two weight-loss trials. One ran 12 weeks. The other ran 24 weeks in 536 subjects and failed.
• Rabbits with knee damage. AOD-9604 injected into the joint gave better cartilage scores than saline.

None of the sources cited here reports a trial in lean people. No completed human trial cited here backs AOD-9604 as a standalone fat-loss agent. It is not an approved treatment for weight loss.

Is AOD-9604 Legal to Buy for Research?

AOD-9604 is not an FDA-approved drug. The FDA lists it on its compounding safety-risk page, in the group nominated and then withdrawn. Cox and colleagues report that it is banned by the World Anti-Doping Agency (WADA). That matters for any tested athlete.

The same paper reports that it is sold on several websites. It was also found in seized vials in the USA.

The rules are shifting. Our pages on the FDA reclassification process and the grey market problem and legal peptide access cover the wider picture.

The Honest Summary: What AOD-9604 Is and Is Not

AOD-9604 is a fragment of human growth hormone. In obese rodents it cut weight gain and raised fat breakdown, without the blood sugar effect of full hGH. In people, 1 mg a day gave 2.6 kg of loss over 12 weeks, against 0.8 kg on placebo. A larger 24-week trial failed, and development stopped in 2007.

So it is not a proven fat-loss therapy. The FDA says it has identified no, or only limited, safety information. The open question is whether the animal results carry over to people at all.

All content on this page is for educational purposes and research use only. AOD-9604 is not an approved medication. A qualified clinician familiar with your individual health status can advise on any peptide protocol.